CEO Ron Bentsur is scheduled to speak at 10:30 a.m. ET in New York; Nuvectis says a webcast will be available in the ...

Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ...

Opportunities center on targeted complement inhibitors, biologics, small molecules, RNA and gene therapies for rare diseases across ophthalmology, hematology and immunology.Dublin, Sept. 16, 2026 ...

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Today it holds ex-China rights to the world’s first approved once-daily oral Factor B inhibitor and, as of this morning, to a breakthrough-designated cancer drug. NXP200, the company’s oral, ...

One of the most frustrating patterns in modern cancer treatment is that a therapy which works brilliantly at first can ...

Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about ...

CBD could help strengthen a light-based cancer treatment’s ability to destroy tumor cells, according to a new scientific ...

Paroxysmal nocturnal hemoglobinuria has long been one of hematology’s cruelest puzzles: a rare, acquired stem-cell mutation that leaves red blood cells defenseless against the body’s own com ...

Gains were durable, open-label extension suggests ...

New clearance strategies and humanized cell models are giving researchers faster tools to confront biology’s unusually ...

IntroductionThe treatment of malignant lymphoma has always been centered on anticancer drugs. However, treatment strategies, especially for B-cell lymphoma, have changed significantly over the last 10 ...